Senolytics and the first useful human questions

Updated 11 Oct 2026

The human evidence now includes a positive randomized liver trial. Its disease-specific result does not establish general anti-aging or training benefits.

What is being targeted

Senescent cells have entered a state of persistent growth arrest and can release signals affecting nearby tissue. The rationale for a senolytic is to remove selected senescent cells, rather than merely lower an inflammatory blood marker. Senescence is also context dependent: in an original mouse study, transient senescent cells helped skin wounds close through a secreted repair signal. This is one reason “remove all old cells” is a poor statement of the therapeutic goal. Original wound-healing experiment.

A useful human trial needs to identify the intervention, tissue, disease or functional outcome, and harms. It also needs to distinguish evidence of changing a senescence-associated measurement from proof that a selective cell-removal mechanism caused a health improvement.

October 2026: a positive liver-disease trial

A double-blind trial randomized 31 adults with fibrotic metabolic dysfunction-associated steatohepatitis (MASH) to dasatinib plus quercetin or placebo for 21 weeks. The primary biopsy outcome—at least one-stage fibrosis improvement without worsening MASH—occurred in 8/17 versus 1/14: difference 40 percentage points (95% CI 8.2–64.5; P=.021). Three blinded pathologists assessed biopsies. Original trial.

Four missing biopsies counted as nonresponses; worst-case sensitivity lost significance. Baseline diabetes differed. Adverse events affected 14/17 versus 6/14; one participant withdrew with gastrointestinal symptoms and fatigue. Gene-signature changes accompanied the result. Grant-funded; two authors disclosed senolytic-patent interests. This small, short disease-specific trial established neither longer life nor improved healthy training.

Bone: the overall result and subgroup result differ

A 2024 randomized trial studied the same drug combination in 60 postmenopausal women. The primary endpoint, a bone-resorption marker after 20 weeks, did not differ between groups: P=0.611. A bone-formation marker improved early, but that difference was not sustained at the final 20-week assessment. Original Nature Medicine trial.

Exploratory analyses suggested a stronger response among women with higher baseline T-cell p16 expression, including a change in radius bone density. This supports a testable hypothesis about selecting a population. It does not turn the overall null primary result into a successful fracture-prevention trial. Blood p16 measured in a research setting is also not a validated do-it-yourself rule for deciding who should take the combination.

Lung fibrosis: feasibility is not demonstrated efficacy

The original 2019 pulmonary-fibrosis pilot reported improvements in physical function in 14 treated participants, but had no placebo group. Original uncontrolled pilot. The later 2023 randomized pilot assigned only six participants to dasatinib plus quercetin and six to placebo. Its main purpose was feasibility and tolerability. Exploratory pulmonary, frailty, and physical-function measures did not appear meaningfully different between groups. Original randomized lung trial.

Nonserious adverse events were more numerous with the drug combination: 65 versus 22. With this sample and brief exposure, neither a major clinical benefit nor uncommon risks could be established. The earlier uncontrolled improvement remains hypothesis generating; the randomized study does not confirm a functional treatment effect. A follow-up publication discussing the same participants should also not be counted as an independent replication.

Human tissue evidence is a separate milestone

An open-label study in nine people with diabetic kidney disease examined adipose tissue, skin, and blood before and after treatment. It found decreases in several senescence-associated cell markers and circulating factors after dasatinib plus quercetin. This was important early evidence that an administered intervention could alter these measurements in human tissue. Original diabetic-kidney-disease pilot.

The absence of a randomized control group limits causal interpretation, and the reported measurements were not proof of improved kidney survival or healthy-person lifespan. A change in fat or skin tissue should not be described as a measured clearance of senescent cells throughout the entire body. The scientific next step is to connect target engagement with a durable clinical benefit.

Fisetin and quercetin alone are different interventions

Quercetin is one component of the studied combination; dasatinib is a potent prescription kinase inhibitor. A positive combination trial does not show that quercetin alone reproduces the effect. Likewise, fisetin is a different molecule, with its own exposure and clinical research. It cannot borrow the MASH study’s efficacy or safety result.

A 2026 publication describes TROFFi, a planned randomized fisetin study in 88 postmenopausal breast-cancer survivors with reduced physical function after chemotherapy. Its proposed primary endpoint is change in six-minute walking distance. The registry was still recruiting in its July 2026 update and had no posted results when checked for this article. The published protocol is a useful question, not a positive finding. Original TROFFi protocol, official trial record.

More generally, a fisetin or quercetin study that changes an inflammatory signal would not automatically demonstrate selective removal of senescent cells. A normal food serving, a concentrated supplement, and a drug combination also produce different exposures. They should not be collapsed into one category merely because a molecule occurs in plants.

The benefit-risk question remains medical

The current dasatinib label establishes leukemia indications and describes risks including suppression of blood-cell production, bleeding, fluid retention, cardiovascular effects, and important drug interactions. Those are material considerations for a research intervention. The particular risks and rates in cancer treatment cannot simply be assigned unchanged to short intermittent studies, but the short studies cannot erase them either. Official dasatinib prescribing information.

For my present decision, the clinical evidence reviewed here does not establish prevention of age-related disease in healthy young adults, better training adaptation, or treatment of shoulder discomfort. The new liver result deserves replication and longer follow-up; the bone, lung, and tissue studies provide distinct questions and limitations. This keeps senolytics as a research topic alongside the metabolic frontier and recovery investigation, rather than a requirement of my daily food plan.

Back to investigations